| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,435 | 1,705 | 23.07. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | BPC INSTRUMENTS AB: BPC Instruments receives ISO 9001 certification for quality management | 1 | Cision News | ||
| 26.05. | Bulletin from the Annual General Meeting of BPC Instruments AB (publ) | 1 | Cision News | ||
| BPC INSTRUMENTS Aktie jetzt für 0€ handeln | |||||
| 19.05. | BPC Instruments AB: BPC Instruments partners with AURI on anaerobic digestion experimentation in the United States | 785 | PR Newswire | LUND, Sweden, May 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") has entered a strategic collaboration with the Agricultural Utilization Research Institute ("AURI") to improve... ► Artikel lesen | |
| 06.05. | BPC Instruments AB (publ) reports results for Q1 2026 | 2 | Cision News | ||
| 30.04. | BPC INSTRUMENTS AB: BPC Instruments discloses preliminary figures for the first quarter of 2026 | 1 | Cision News | ||
| 29.04. | BPC Instruments AB (publ) publishes Annual Report for 2025 | 1 | Cision News | ||
| 23.04. | Notice of Annual General Meeting in BPC Instruments AB (publ) | 1 | Cision News | ||
| 17.03. | BPC INSTRUMENTS AB: BPC Instruments launches BPC Connect - a smart hub for the BPC Go platform | 2 | Cision News | ||
| 11.03. | BPC INSTRUMENTS AB: BPC Instruments launches BPC Academy to strengthen customer value and long-term engagement | 3 | Cision News | ||
| 26.02. | BPC Instruments AB: BPC Instruments reports results for 2025 | 393 | PR Newswire | LUND, Sweden, Feb. 26, 2026 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the year-end report for the year 2025. The year-end report is available as... ► Artikel lesen | |
| 24.02. | BPC Instruments AB: BPC Instruments receives two repeat orders from Denmark within biogas applications | 819 | PR Newswire | LUND, Sweden, Feb. 24, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received two repeat orders from Denmark within biogas applications with a total value of approximately SEK 1.1 million.... ► Artikel lesen | |
| 19.02. | BPC Instruments AB: BPC Instruments secures order for BPC Blue system from global testing and certification group | 605 | PR Newswire | LUND, Sweden, Feb. 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received an order valued at approximately SEK 0.8 million for BPC's most advanced BPC Blue configuration, including... ► Artikel lesen | |
| 02.02. | BPC INSTRUMENTS AB: BPC Instruments strengthens the BPC Go platform - launches new solution for advanced process data logging | 1 | Cision News | ||
| 16.12.25 | BPC Instruments AB: BPC Instruments partners with SixRing to provide quality assurance for the EU and UK biomethane markets | 620 | PR Newswire | LUND, Sweden, Dec. 16, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has entered into a collaboration with SixRing, the Canadian technology company behind Stimulose, a new feedstock additive... ► Artikel lesen | |
| 20.11.25 | BPC Instruments AB: BPC Instruments secures new order for several BPC Go units from a international energy group | 620 | PR Newswire | LUND, Sweden, Nov. 20, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received a new order valued at approximately SEK 0.9 million for several BPC Go units from a major international... ► Artikel lesen | |
| 12.11.25 | BPC Instruments AB: BPC Instruments reports results for the period January - September 2025 | 980 | PR Newswire | LUND, Sweden, Nov. 12, 2025 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the interim report for the period January 1 - September 30, 2025. The interim report is available... ► Artikel lesen | |
| 02.09.25 | BPC Instruments AB: BPC Instruments expands into the textile sector - receives order from a global materials company | 400 | PR Newswire | LUND, Sweden, Sept. 2, 2025 /PRNewswire/ -- BPC Instruments AB (publ) is extending the industrial application of its BPC® Blue platform into the textiles & apparel sector, broadening the... ► Artikel lesen | |
| 27.08.25 | BPC Instruments AB: BPC Instruments reports results for H1 and Q2 2025 | 594 | PR Newswire | LUND, Sweden, Aug. 27, 2025 /PRNewswire/ -- BPC Instruments (publ) hereby publishes the half-year report for the period January 1 - June 30, 2025. The half-year report is available as an... ► Artikel lesen | |
| 05.08.25 | BPC Instruments AB: BPC Instruments secures 4.4 MSEK order from a public research organisation in the Philippines | 490 | PR Newswire | LUND, Sweden, Aug. 5, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received an order valued at approximately SEK 4.4 million from a public research institution in the Philippines, operating... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,575 | +3,13 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,38 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,260 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,880 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,370 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 322,57 | +0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,25 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| ERASCA | 19,330 | -0,05 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 58,58 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| CG ONCOLOGY | 71,13 | +0,01 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,970 | -0,07 % | Summit Therapeutics says cash crunch could impact its ability to continue | ||
| BEAM THERAPEUTICS | 25,890 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| VERA THERAPEUTICS | 36,320 | -0,08 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| JANUX THERAPEUTICS | 15,720 | 0,00 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 27,460 | +0,04 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% |